Systemic oxytocin treatment modulates alpha 2-adrenoceptors in telencephalic and diencephalic regions of the rat.
Systemic subchronic oxytocin treatment significantly and substantially increased the B(max) values of the alpha 2 agonist [(3)H]UK14.304 binding sites in the hypothalamus, the amygdala and the paraventricular thalamic nucleus of the rat as shown by quantitative receptor autoradiography. These results suggest that long-term modulation of autonomic and neuroendocrine functions and emotional behaviours elicited by brain oxytocin may involve enhancement of central alpha 2-adrenoceptor function.
Díaz-Cabiale
Z
Z
Department of Neuroscience (BZ-lab), Karolinska Institute, S 171 77 Stockholm, Sweden. zaida.diaz@neuro.ki.se
Petersson
M
M
Narváez
J A
JA
Uvnäs-Moberg
K
K
Fuxe
K
K
D000316:Adrenergic alpha-Agonists / Q000493:pharmacokinetics; D000679:Amygdala / Q000502:physiology; D000818:Animals; D001345:Autoradiography; D000068438:Brimonidine Tartrate; D004027:Diencephalon / Q000187:drug effects / Q000502:physiology*; D007031:Hypothalamus / Q000502:physiology; D008297:Male; D010121:Oxytocin / Q000008:administration & dosage / Q000494:pharmacology*; D010286:Paraventricular Hypothalamic Nucleus / Q000502:physiology; D011810:Quinoxalines / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D018341:Receptors, Adrenergic, alpha-2 / Q000187:drug effects / Q000502:physiology*; D013687:Telencephalon / Q000187:drug effects / Q000502:physiology*; D014316:Tritium
D000316:Adrenergic alpha-Agonists; D011810:Quinoxalines; D018341:Receptors, Adrenergic, alpha-2; D014316:Tritium; D000068438:Brimonidine Tartrate; D010121:Oxytocin